NCT04724447已完成1 期
EXPERIMENTAL ANTIVIRAL TREATMENT OF CYTOMEGALOVIRUS IN DEPRESSION: AFFECTIVE, NEURAL, AND INFLAMMATORY MECHANISMS
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- White matter integrity of the inferior fronto-occipital fasciculus (IFOF)
研究概览
简要总结
This study aims to determine whether treatment of CMV positive (CMV+) individuals with major depressive disorder (MDD) with valganciclovir (VGCV) alters neural circuitry, reduces inflammation, and improves depressive behavior and symptoms to a greater extent than placebo. In this double-blind, randomized placebo-controlled, parallel group trial, 24 individuals with a Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR) scale score ≥ 14 will be enrolled to participate in an 8-week treatment study. Participants will be randomized with a 1-1 ratio to receive 900 milligrams (mg) VGCV or placebo to be taken orally once per day. Participants will complete a 2-hour pre-screen, a baseline blood-draw, clinical evaluation, and MRI scan (visit 2), a clinical evaluation, blood draw, and MRI scan at week 4 (visit 6), and a clinical evaluation, blood draw, and MRI scan at week 8 (visit 10). Weekly telephonic visits to assess depressive symptoms and side effects will held between the in-person assessments.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provision of signed and dated informed consent form
- •Stated willingness to comply with all study procedures and availability for the duration of the study
- •Male or female, aged 18-65 years
- •Diagnosis with major depressive disorder (MDD)
- •Current symptoms of depression, that is, a QIDS-SR score ≥
- •Unmedicated for at least 4 weeks (8 weeks for fluoxetine).
- •In good general health as evidenced by medical history, physical exam, and safety labs
- •Ability to take oral medication and be willing to adhere to the VGCV regimen
- •For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 4 weeks after the end of VGCV administration
- •For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner during the study and for at least 90 days after the study.
- •Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study duration
排除标准
- •General Exclusion Criteria:
- •Pregnancy
- •Breast-feeding
- •Unwillingness to avoid pregnancy during the study due to the possible teratogenic effects of valganciclovir
- •Medical Conditions:
- •Moderate to severe traumatic brain injury (>30 min. loss of consciousness or >24 hours posttraumatic amnesia) or other neurocognitive disorder with evidence of neurological deficits.
- •Presence of co-morbid medical conditions not limited to but including cardiovascular (e.g., history of acute coronary event, stroke) and neurological diseases (e.g., Parkinson's disease), as well as pain disorders.
- •Presence of co-morbid inflammatory disorders such as rheumatoid arthritis or other autoimmune disorders.
- •Presence of an uncontrolled medical condition that is deemed by the investigators to interfere with the proposed study procedures, or to put the study participant at undue risk.
- •Presence of a chronic infection (e.g. HIV) that may elevate pro-inflammatory cytokines.
- •Presence of an acute infectious illness (e.g. SARS CoV-2) or receipt of a vaccination in the week prior to enrollment.
- •Psychiatric Disorders:
- •Current significant suicidal ideation (intent to commit suicide or making specific plans for suicide)
- •Suicide attempt within the last 6 months
- •Lifetime history of schizophrenia, schizophreniform, schizoaffective disorder, delusional disorder
- •History of a manic or hypomanic episode not better accounted for by substance use
- •Moderate to severe substance use disorder within the last year, excluding cannabis or nicotine use disorder
- •Moderate or severe alcohol use disorder
- •Positive urine toxicology (except cannabis)
- •Contraindications to Valganciclovir:
- •Myelosuppressive chemotherapy or radiation therapy
- •Absolute neutrophil count < 500/mm3
- •Platelet count < 25,000/mm3
- •Hemoglobin < 8g/dL
- •Impaired renal function (estimated glomerular filtration rate <60mL/minute/1.73m2)
- •Sensitivity to VGCV, ganciclovir or other nucleoside analogues
- •Medications that could interact with VGCV (see below):
- •Prohibited Medications Abacavir Lamivudine, 3TC Amikacin Aminoglycosides Amphotericin B cholesteryl sulfate complex (ABCD) Amphotericin B lipid complex (ABLC) Amphotericin B liposomal (LAmB) Amphotericin B Aprotinin Bacitracin Bictegravir; Emtricitabine; Tenofovir Alafenamide Cisplatin Colchicine; Probenecid Cyclosporine Dapsone Darunavir; Cobicistat; Emtricitabine; Tenofovir alafenamide
- •Didanosine, ddI:
- •Doravirine; Lamivudine; Tenofovir disoproxil fumarate Doxorubicin Efavirenz; Emtricitabine; Tenofovir Efavirenz; Lamivudine; Tenofovir Disoproxil Fumarate Elvitegravir; Cobicistat; Emtricitabine; Tenofovir Alafenamide Elvitegravir; Cobicistat; Emtricitabine; Tenofovir Disoproxil Fumarate Emtricitabine Emtricitabine; Rilpivirine; Tenofovir alafenamide Emtricitabine; Rilpivirine; Tenofovir disoproxil fumarate Emtricitabine; Tenofovir alafenamide Emtricitabine; Tenofovir disoproxil fumarate Entecavir Flucytosine Gentamicin Hyaluronidase, Recombinant; Immune Globulin Hydroxyurea Imipenem; Cilastatin Immune Globulin IV, IVIG, IGIV Kanamycin Lamivudine; Tenofovir Disoproxil Fumarate Mycophenolate Paromomycin Pentamidine Plazomicin Polymyxin B Streptomycin Sulfamethoxazole; Trimethoprim, SMX-TMP, Cotrimoxazole Tacrolimus Talimogene Laherparepvec Telbivudine Tenofovir Alafenamide Tenofovir, PMPA Tobramycin Trimethoprim Vancomycin Vinblastine Vinca alkaloids Vincristine Liposomal Vincristine Vinorelbine Zidovudine
- •Other Medications:
- •Current and/or past regular use of hormone-containing medications (excluding contraceptives)
- •Current use of non-steroid anti-inflammatory drugs that is deemed by the investigators to potentially confound the results of the study or the increase risk of renal impairment (e.g. more than 3 days/week).
- •Current and/or past regular use of immune modifying drugs that target specific immune responses such as TNF antagonists
- •Chronic use of antibiotics such as isotretinoin or minocycline because of their potential effects on the microbiome and immune function.
- •Current and/or past regular use of antiarrhythmic, anti-anginal, and anticoagulant drugs (does not apply where medications are taken for different purpose).
- •Inclusion of individuals reporting other types of medications or supplements not listed or considered thus far will be at the discretion of the PI based on their potential to affect immune function, brain function or brain blood flow.
- •Contraindications to MRI:
- •Cardiac pacemaker, metal fragments in eyes/skin/body (shrapnel), aortic/aneurysm clips, prosthesis, by-pass surgery/coronary artery clips, hearing aid, heart valve replacement, shunt (ventricular or spinal), electrodes, metal plates/pins/screws/wires, or neuro/bio-stimulators (TENS unit), persons who have ever been a professional metal worker/welder, history of eye surgery/eyes washed out because of metal, vision problems uncorrectable with lenses, inability to lie still on one's back for 60 minutes; prior neurosurgery; tattoos or cosmetic makeup with metal dyes, unwillingness to remove body piercings, and pregnancy.
- •Claustrophobia severe enough to prevent scanning
- •Health Factors:
- •BMI > 38 because of the effects of obesity on pro-inflammatory cytokine activity
- •Clinically significant abnormalities on screening laboratory tests
- •Non-English speaking participants:
- •The majority of the assessments proposed for this study have not been translated from English, thus, non-English speaking volunteers will be excluded.
研究组 & 干预措施
Placebo
Placebo Comparator
Placebo equivalent of 900 milligrams (mg) VGCV to be taken orally once per day for 8 weeks.
干预措施: Placebo (Drug)
Valganciclovir
Experimental
900 milligrams (mg) valganciclovir (VGCV) to be taken orally once per day for 8 weeks.
干预措施: Valganciclovir (Drug)
结局指标
主要结局
White matter integrity of the inferior fronto-occipital fasciculus (IFOF)
时间窗: 8 weeks
Mean fractional anisotropy of the IFOF measured with diffusion tensor imaging
次要结局
- Volume of the medial temporal gyrus (MTG)(8 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Effect of ganciclovir eye-drops for corneal endothelitis caused by cytomegalovirus infectioCytomegalovirus coreal endotheliitisCytomegalovirus, Coreal endotheliitisJPRN-jRCTs021180030Tando Toshio10
招募中
不适用
Prophylaxis Guided by Cytomegalovirus-specific T Cell Immunity to Prevent Cytomegalovirus Disease in Lung Transplant RecipientsLung DiseasesNCT06494033University of Miami100
已完成
2 期
Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe PneumoniaCytomegalovirus InfectionsHIV/AIDSTuberculosisPneumoniaNCT03915366Hospital Universitario 12 de Octubre563
已完成
3 期
Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell TransplantationCancerNCT00045292Fred Hutchinson Cancer Center
已完成
不适用
A Study of Lobucavir in Patients With AIDSCytomegalovirus InfectionsHIV InfectionsNCT00002352Bristol-Myers Squibb30